Notice: eScholarship will undergo scheduled maintenance from Tuesday, January 21 to Wednesday, January 22. Some functionality may not be available during this time. Learn more at eScholarship Support.
Sorafenib is a multi-kinase inhibitor approved for the treatment of renal cell and hepatocellular carcinoma. Adverse cutaneous reactions are a very common side effect of the medication. We report the development of hidradenitis suppurativa (HS) in a patient after initiation of treatment with sorafenib. HS is marked by recurrent deep painful nodules, fluctuant abscesses, and draining sinus tracts most frequently occurring in the groin and axilla. To our knowledge, sorafenib-induced HS in the axillary and inguinal skin folds has not been previously reported.
Main Content
For improved accessibility of PDF content, download the file to your device.
